Order an embecta
Patient Counseling Toolbox
embecta, formerly part of BD

PROBLEM

TOO MUCH INJECTION FORCE

76%

of patients surveyed reported applying too much injection force1*

Too much injection force can lead to intramuscular injection, which may affect proper insulin absorption, increase the risk of hypoglycemia, and lead to increased pain.²

Contoured needle base

SOLUTION

CONSISTENT INJECTION DEPTH

BD Nano™ 2nd Gen Pen Needles, with a contoured needle base, are estimated to reduce intramuscular injection risk by

2-8x

vs 4mm posted-base pen needles3†

SOLUTION

CONSISTENT INJECTION DEPTH

Contoured needle base

BD Nano™ 2nd Gen Pen Needles, with a contoured needle base, are estimated to reduce intramuscular injection risk by

2-8x

vs 4mm posted-base pen needles3†

Explore more features of BD Nano™ 2nd Gen Pen Needles

The combination of innovative features on BD Nano™ 2nd Gen Pen Needles was found by people with diabetes to significantly reduce overall injection pain and make the injection experience easier compared to other pen needles studied.4‡§

Contoured needle base

The contoured needle base allows for a more consistent 4mm target injection depth.3||

5-bevel tip

The 5-bevel needle tip provides more comfortable and less painful injections.5¶

Ultra-thin wall technology

Ultra-thin wall technology increases the flow of insulin, giving patients greater confidence that the complete dose was delivered.6#

Ergonomic design

The wider outer cover is easier to attach to the pen device, and the larger inner needle shield is easier to grip and remove before an injection.⁴**††

Contoured needle base

The contoured needle base allows for a more consistent 4mm target injection depth.3||

5-bevel tip

The 5-bevel needle tip provides more comfortable and less painful injections.5¶

Ultra-thin wall technology

Ultra-thin wall technology increases the flow of insulin, giving patients greater confidence that the complete dose was delivered.6#

Ergonomic design

The wider outer cover is easier to attach to the pen device, and the larger inner needle shield is easier to grip and remove before an injection.4**††

Discover resources to help you support patients with diabetes

Education and Resources
*

Results from a survey of 230 Canadian patients with diabetes. 76% of patients reported applying excess pressure onto the skin when injecting.

†

The study used in-silico probability model of needle penetration depth for posted-hub 4mm pen needles and average human tissue thickness measurements across a range of injection forces and recommended sites, pooled across gender and BMI.

‡

226 patients with diabetes on insulin treatment were studied with a 150mm visual analog scale (mean scores of >0mm; clinically significant difference of ≥5mm). BD Nano™ 2nd Gen demonstrated superiority vs all comparator groups combined for less injection pain [(P<0.05) (mean +15.5mm, 95% CI, +8.9 to +22.1mm)].

§

226 patients with diabetes on insulin treatment were studied with a 150mm visual analog scale (mean scores of >0mm; clinically significant difference of ≥5mm). BD Nano™ 2nd Gen demonstrated superiority vs all comparator groups combined for feeling more comfortable throughout injection experience and for overall ease of use [comfort (P<0.05) (mean +18.0mm, 95% CI, +11.6 to +24.3mm)]; [easier (P<0.05) (mean 19.9mm, 95% CI, +13.8 to +25.9mm)].

||

1188 injections administered in swine across a range of injection forces using 20 μL of iodinated contrast delivered with BD Nano™ 2nd Gen vs three 4mm posted-hub pen needles. Measurements were obtained via fluoroscopic imaging. BD Nano™ 2nd Gen more closely achieved the 4mm target injection depth with less variability (P=0.006).

Compared to 3-bevel pen needles; 86 patients with diabetes participated in a randomized, non-inferiority crossover trial. During the blinded portion of the study there was no difference in pain; during the non-blinded portion of the study there was statistical difference, P<0.01.

#

198 patients with diabetes were included in this prospective, multicenter, randomized, open-label, 2-period, crossover study to evaluate differences in perceived thumb force and in confidence that the full dose of insulin was delivered, between the participants’ usual pen needle and the corresponding extrathin wall (XTW) pen needle while using a manually operated insulin pen. Both outcomes were considered statistically significant if the 95% CI for the mean visual analog scale score was either positive (XTW preferred) or negative (current pen needle preferred). Significant differences favoring XTW pen needles were seen for perceived thumb force and confidence that the full dose was delivered by 28.4mm (95% CI, 23.7 to 33.2), and 24.4mm (95% CI, 19.7 to 29.1), respectively (all, P<0.001).

**

226 patients with diabetes on insulin treatment were studied with a 150mm visual analog scale (mean scores of >0mm; clinically significant difference of ≥5mm). BD Nano 2nd Gen demonstrated superiority vs all comparator groups combined for ease of grip and removal of the inner shield [grip (P<0.05) (mean +23.8mm, 95% CI, +18.1 to +29.4mm)]; [removal (P<0.05) (mean +24.4mm, 95% CI, +18.9 to +29.9mm)].

††

226 patients with diabetes on insulin treatment were studied with a 150mm visual analog scale (mean scores of >0mm; clinically significant difference of ≥5mm). BD Nano™ 2nd Gen demonstrated superiority vs all comparator groups combined for ease of attachment [(P<0.05) (mean +21.8mm, 95% CI, +16.1 to +27.6mm)].

References: 1.Bari B, Corbeil MA, Farooqui H, et al. Insulin injection practices in a population of Canadians with diabetes: an observational study. Diabetes Ther. 2020;11(11):2595-2609. 2. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91(9):1231-1255. 3. Rini C, Roberts BC, Morel D, et al. Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol. 2019;13(3):533-545. 4. Whooley S, Briskin T, Gibney MA, et al. Evaluating the user performance and experience with a reengineered 4 mm x 32G pen needle: a randomized trial with similar length/gauge needles. Diabetes Ther. 2019;10(2):697-712. 5. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012;6(2):328-335. 6. Aronson R, Gibney M, Oza K, et al. Insulin pen needles: effects of extra-thin wall needle technology. Clin Ther. 2013;35(7):923-933.